Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 305 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Follow-Up Questions
Bicycle Therapeutics PLC 的 CEO 是誰？
Dr. Kevin Lee 是 Bicycle Therapeutics PLC 的 Chief Executive Officer，自 2015 加入公司。
BCYC 股票的價格表現如何？
BCYC 的當前價格為 $7.26，在上個交易日 decreased 了 0%。
Bicycle Therapeutics PLC 的主要業務主題或行業是什麼？
Bicycle Therapeutics PLC 屬於 Biotechnology 行業，該板塊是 Health Care
